Amgen sues competitor to block generic version of Sensipar

You are here: Home > Central Coast Health Watch > Current Article

Amgen sues competitor to block generic version of Sensipar

By Staff Report / Thursday, July 5th, 2018 / Comments Off on Amgen sues competitor to block generic version of Sensipar

Thousand Oaks biotech powerhouse Amgen filed a complaint in North Carolina District Court against a competitor seeking to make a generic of its drug Sensipar, used by patients with chronic kidney disease. Accord Healthcare, a Durham, N.C.-based subsidiary of Indian company Intas Pharmaceuticals, allegedly alerted Amgen that it had filed an Abbreviated New Drug Application…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.